Aim. To evaluate clinical efficiency of sulodexide (glycosoaminoglycan) for the treatment of patients with type 2 diabetes mellitus (DM2) and diabeticnephropathy (DN) at the stage of microalbuminuria (MAU). Materials and methods. A total of 30 patients with DM2 and MAU were examined 15 of whom were given sulodexide (200 mg daily) for 6 months.The following parameters were measured before, 3 and 6 months after the onset of therapy: HbA1c level, biochemical characteristics, highly sensitiveCRB, MAU in morning urine samples, soluble intercellular and vascular cell adhesion molecules-1, blood coagulation and anticoagulation factors(PTI, fibrinogen, thrombin time, coagulation factors VII, VIII, X, Willebrand factor), tissue plasminogen activator, and its inhibitor. Results. Sulodexide produced significant positive effect on albumin excretion in urine. It exerted antithromotic and profibrinolytic action and improvedendothelial function. Taken together, these properties of sulodexide give reason to recommend it as a protector of different vascular segments. Conclusion. Significant positive effect of sulodexide on albumin excretion in urine coupled to its multifactor activity, convenience of therapeutic application,low risk of complications, good tolerability, and safety in aged patients with DM2 permit to consider it as a promising tool for the treatmentof DM2 with MAU.

To achieve glycemic targets, as the main preventive measure for vascular complications, patients with type 1 diabetes need lifelong administration of insulin in a regimen that allows them to have euglycemia both before and after eating. For this, optimal insulin therapy regimens have been created, which necessarily include short-acting insulin (with the main meal) and medium or long-acting insulin as basal. This mode of administration allows you to maximize bring the daily fluctuations of insulin administered to the natural rhythm of insulin secretion in healthy people.

Diabetic nephropathy (DN) develops in 20-45% of the patients with diabetes mellitus. Hyperglycemia, arterial hypertension, and dyslipidemia are the most important risk factors of this complication. The prevention of DN is to make an adequate glycemia (the level of HbА1с

Медицина располагает широким спектром знаний о факторах риска цереброваскулярных заболеваний при СД 2 типа и широким диагностическим потенциалом для их выявления. Эффективной может быть признана только стратегия, направленная на максимальную коррекцию всех имеющихся факторов риска.